743 INCLINE-101: preliminary safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TAC-001 (TLR9 agonist conjugated to a CD22 mAb) in patients with advanced or metastatic solid tumors

• Joshua Lee,
• Anna Pavlick,
• Feng Jin,
• Cesar Perez,
• Martin Gutierrez,
• Anthony El-Khoueiry,
• Ons Harrabi,
• Jason Henry,
• Sunnie Kim,
• Sangeetha Bollini,
• Kevin N Heller,
• Timothy Humphries

Affiliations

Joshua Lee

1The Royal London Hospital, Whitechapel, UK

Anna Pavlick

7NYU Langone Medical Center, New York, NY, USA

Feng Jin

10ALX Oncology Inc., Burlingame, CA, United States

Cesar Perez

1SCRI at Florida Cancer Specialists, Lake Nona, FL, USA

Martin Gutierrez

5Hackensack University Medical Center, Hackensack, NJ, USA

Anthony El-Khoueiry

4USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA

Ons Harrabi

1Tallac Therapeutics, Burlingame, CA, USA

Jason Henry

1Sarah Cannon Research Institute, Denver, CO, USA

Sunnie Kim

3University of Colorado Denver AMC, Aurora, CO, USA

Sangeetha Bollini

7Tallac Therapeutics, Burlingame, CA, USA

Kevin N Heller

8Tallac Therapeutics, Potomac, MD, USA

Timothy Humphries

9Linear Clinical Research Ltd, Nedlands, Western Australia, Australia